验证码已发送至您的邮箱或手机,请查收。
Research Code APT-070; APT-070C
CAS No.
Phase I Pending
An angiogenesis inhibitor potentially for the treatment of age-related macular degeneration (AMD).
Research Code LD22-4
CAS No.
Research Code MK-8719
CAS No.
HIV vaccine (Institute of Human Virology/Profectus Biosciences)
Phase I Active
An antiviral immune modulating (AIM) therapeutic potentially for the treatment of HIV infection.
Research Code IHV 001; IHV-01
CAS No.
Research Code Anti-LeY-CAR
CAS No.
Phase II Active
Research Code NEO-101; NEO-102; NPC-1-C
CAS No.
(Vaxira®) Approved
Research Code 1E10
CAS No.
946832-34-4
Phase II Active
Research Code IMM-124E; IMM122-I
CAS No.
Phase II Active
Research Code SGM-101
CAS No.
Research Code MDX-1303; MAb-1303
CAS No.
Research Code R-89674
CAS No.
147084-10-4(Alcaftadine)
Phase I Active
A CD19 and CD3 targeted bispecific TandAb potentially for the treatment of non-Hodgkin's lymphoma.
Research Code AFM-11
CAS No.
Phase II Active
Research Code AFM-13
CAS No.
Anti-CD34 mab-sirolimus (OrbusNeich)
Approved
An anti-CD34 antibody-coated drug-eluting stent used for prevention of coronary artery restenosis.
Research Code
CAS No.
53123-88-9
(Thymogen®) Phase III Discontinued
An angiogenesis inhibitor potentially for the treatment of Kaposi's sarcoma.
Research Code IM-862
CAS No.
237068-57-4(Oglufanide disodium)
38101-59-6(Oglufanide)
Research Code BAX-2200; CHS-0214
CAS No.
185243-69-0 (Etanercept)
Adalimumab biosimilar (Coherus BioSciences)
Phase III Active
A tumor necrosis factor α (TNFα) inhibitor potentially for the treatment of plaque psoriasis.
Research Code CHS-1420
CAS No.
331731-18-1 (Adalimumab)
Research Code ARGX-109; GB-224; RYI-008
CAS No.
Phase II Active
Research Code ARGX-110
CAS No.
Research Code ARGX-111
CAS No.
Successful modification
Please choose to cancel the drug